| Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629) |
|---|
| 12/06/2001 | WO2001091793A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091775A2 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | WO2001091671A1 Xenograft heart valves |
| 12/06/2001 | WO2001068805A8 Human olfactory receptors and genes encoding same |
| 12/06/2001 | WO2001053500A8 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides |
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001052614A3 Selecting and producing t cell peptide epitopes |
| 12/06/2001 | WO2001051644A3 ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN Cν3 AND Cν4 DOMAINS |
| 12/06/2001 | WO2001049717A3 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity |
| 12/06/2001 | WO2001048240A3 Implication of a known gene named cp2/lsf-lbp-1 in alzheimer's desease |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001046224A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/06/2001 | WO2001042421A3 Long-term cell culture compositions and genetically modified animals derived therefrom |
| 12/06/2001 | WO2001038495A3 Method for producing a thrombocyte preparation and a thrombocyte preparation |
| 12/06/2001 | WO2001034647A3 Animal collagens and gelatins |
| 12/06/2001 | WO2001034646A3 Recombinant gelatins |
| 12/06/2001 | WO2001032864A3 Gpcr-kd5 polypeptides and dna sequences thereof |
| 12/06/2001 | WO2001027630A3 Methods to identify compounds that modulate neuronal activity |
| 12/06/2001 | WO2001027150A3 Anthozoa derived chromo/fluoroproteins and methods for using the same |
| 12/06/2001 | WO2001023421B1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 12/06/2001 | WO2001022922A3 Engineering antibodies that bind irreversibly |
| 12/06/2001 | WO2001019800A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2001007021A3 Process for the improvement of spermatozoa fertilization activity |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | WO2000038517A9 Methods for reducing adverse side effects associated with cellular transplantation |
| 12/06/2001 | WO2000011166A9 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| 12/06/2001 | US20010049833 A DNA sequences which are able to inhibit proteins required for cell function, or which control senescence or germination and/or which control protein metabolism, in particular of stored protein |
| 12/06/2001 | US20010049831 Contacting a plant cell with a vector containing a nucleic acid sequence comprising a structural gene encoding FT polypeptide, operably associated with a promoter, to obtain transformed plant cell, producing plant from transformed cell |
| 12/06/2001 | US20010049830 Molecular farming |
| 12/06/2001 | US20010049829 Developmental competence for assisted reproduction and nuclear transfer in pigs |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049360 Betaglycan as an inhibin receptor and uses thereof |
| 12/06/2001 | US20010049357 Promotes dendritic cell maturation in vitro. |
| 12/06/2001 | US20010049144 Genetically engineering a primate for expression of a desired gene, comprising introducing into the primate a transgene of a Rous Sarcoma Virus promoter (RSV) and a nucleic acid sequence heterologous to said RSV promoter; gene therapy |
| 12/06/2001 | US20010049143 Immortalising a human undifferentiated or precursor cell of a given tissue using an immortalising agent that controls activation of the control means to terminate immortalisation and allows differentiation; cultures |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049141 Rapidly dissolving nutritionally complex stable dry powder which can be prepared in variable bulk quantities and can be sterilized by ionizing or ultraviolet irradiation; agglomerating a dry powder nutritive media with a solvent |
| 12/06/2001 | US20010049140 Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| 12/06/2001 | US20010049139 Transplantation of hematopoietic stem cells to repopulate functional hepatocytes; in vitro cell culture of regenerating hepatocytes generated from a human cell population; screening for genetic sequences using hybridization of an RNA probe |
| 12/06/2001 | US20010049138 Disrupting the cell membranes of the tissue sample; denaturing intracellular proteins within the cells and removing the denatured proteins while preserving the extracellular matrix; nerve grafting |
| 12/06/2001 | US20010049136 Deletion of: all or part of the E1A regions, the E1B region coding for the early proteins, E2 or E4 regions, the E1a region and encapsidation region; gene therapy |
| 12/06/2001 | US20010049130 Carrier for pancreatic cells for transplantation into an animal body is formed with a lateral extent much greater than its thickness to enhance its diffusional capability; enhanced hormonal response to stimuli as in blood sugar levels |
| 12/06/2001 | US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections |
| 12/06/2001 | US20010049121 Polypeptides and polynucleotides; drug screening, use in therapy, diagnostic assays |
| 12/06/2001 | US20010049120 Expression vector for consistent cellular expression of the tet on repressor in multiple cell types |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010049089 Storage and maintenance of blood products including red blood cells and platelets |
| 12/06/2001 | US20010048949 Isolated bladder submucosa for tissue reconstruction |
| 12/06/2001 | US20010048930 Incubation lymphocytes with antigen; complexing |
| 12/06/2001 | US20010048921 Forming chimeric bone marrow |
| 12/06/2001 | US20010048919 Virus clearance of neoplastic cells from mixed cellular compositions |
| 12/06/2001 | US20010048917 Skin equivalent and methods of forming and using same |
| 12/06/2001 | CA2414207A1 Adjuvant preparation for the induction of specific immunity |
| 12/06/2001 | CA2413995A1 Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity |
| 12/06/2001 | CA2411655A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2411404A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | CA2411040A1 Therapeutic anti-melanoma compounds |
| 12/06/2001 | CA2410981A1 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | CA2410947A1 Methods for mediating gene suppresion by using factors that enhance rnai |
| 12/06/2001 | CA2410944A1 Cartilage replacement and method for its production |
| 12/06/2001 | CA2410912A1 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410895A1 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | CA2410865A1 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | CA2410736A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410684A1 Method to determine the differentiation potential of a target cell |
| 12/06/2001 | CA2410666A1 Use of eicosanoids for tissue engineering |
| 12/06/2001 | CA2410665A1 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | CA2410515A1 Method of identifying and/or isolating stem cells |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | CA2410480A1 Reagents and methods for identifying and modulating expression of genes regulated by retinoids |
| 12/06/2001 | CA2410470A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2410433A1 Method of forming vertebrate pancreas in vitro |
| 12/06/2001 | CA2410419A1 Improved methods of transfection |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2410051A1 Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes |
| 12/06/2001 | CA2410033A1 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | CA2410015A1 Methods of transducing neural cells using lentivirus vectors |
| 12/06/2001 | CA2409359A1 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2409193A1 Maize glutamine synthetase gene promoter |
| 12/06/2001 | CA2408406A1 Cutinase variants |
| 12/06/2001 | CA2406939A1 Thermostable reverse transcriptases and uses thereof |
| 12/05/2001 | EP1160322A2 Human melanocyte stimulating hormone receptors |
| 12/05/2001 | EP1160316A1 Autonomously growing, invasive fibroblast derived cell line |
| 12/05/2001 | EP1160315A1 Use of biochemical factors for tissue engineering |
| 12/05/2001 | EP1160256A2 Monoclonal antibody specific for beta-A4 peptide |
| 12/05/2001 | EP1160254A1 Human vanilloid receptor-like proteins |
| 12/05/2001 | EP1159439A2 Enhanced system for construction of adenovirus vectors |
| 12/05/2001 | EP1159438A1 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 12/05/2001 | EP1159432A1 Methods for generating and screening novel metabolic pathways |